Sh3bgrl3 Antibody

What is SH3BGRL3 and why is it important in cellular research?

SH3BGRL3 (SH3 Domain Binding Glutamic Acid-Rich Protein Like 3) is a 10 kDa protein that functions as a modulator of glutaredoxin biological activity. The protein plays significant roles in cytoskeleton organization and cellular migration processes, making it an important target in cellular biology research . Recent studies have demonstrated its potential as a prognostic biomarker for urothelial carcinoma and have identified it as a novel binding partner of epidermal growth factor receptor (EGFR), underscoring its relevance in cancer research . SH3BGRL3's relatively small size and specific interactions with other proteins make it particularly interesting for studying protein-protein interaction networks in cellular signaling pathways.

What types of SH3BGRL3 antibodies are commonly used in laboratory research?

The most commonly utilized SH3BGRL3 antibodies in research settings are polyclonal rabbit antibodies that recognize human, mouse, and rat SH3BGRL3. These antibodies are typically generated using either synthetic peptides corresponding to regions within the internal amino acids of human SH3BGRL3 or recombinant proteins . Both conjugated and unconjugated variants are available, including those labeled with FITC, biotin, HRP, and APC for different detection methods . While polyclonal antibodies are predominant in the current research landscape, they vary in their specific targeting regions, with some antibodies recognizing the internal region (AA 24-52) and others targeting broader epitopes (AA 2-93) . This variety allows researchers to select antibodies appropriate for specific experimental conditions and research questions.

What are the validated applications for SH3BGRL3 antibodies?

SH3BGRL3 antibodies have been rigorously validated for several research applications with specific protocols. Western blotting is the most widely validated application, with recommended dilutions typically ranging from 1:500-1:3000, depending on the specific antibody and experimental conditions . Immunohistochemistry (IHC) represents another well-established application, with typical working dilutions of 1:200-1:1600, often requiring antigen retrieval with either TE buffer (pH 9.0) or citrate buffer (pH 6.0) for optimal results . ELISA applications have also been validated, particularly for peptide detection at dilutions between 1:20000-1:40000 . Published research has demonstrated successful detection of SH3BGRL3 in various cell lines including PC-3 cells and U-251 cells for Western blotting, and in human stomach cancer tissue for immunohistochemistry applications .

How should SH3BGRL3 antibodies be optimized for immunohistochemistry applications?

For optimal immunohistochemistry results with SH3BGRL3 antibodies, a systematic optimization protocol should be followed. Begin with antigen retrieval using TE buffer at pH 9.0, which has shown superior results compared to citrate buffer (pH 6.0) for exposing SH3BGRL3 epitopes in fixed tissues . Start with antibody dilutions in the range of 1:400-1:1600 and adjust based on signal-to-noise ratio in your specific tissue type . For human samples, particularly cancer tissues, blocking with 3-5% normal serum from the same species as the secondary antibody for 1 hour at room temperature significantly reduces background staining. Include appropriate positive controls (such as human stomach cancer tissue) where SH3BGRL3 expression has been confirmed . When analyzing results, pay careful attention to membrane localization, as SH3BGRL3 has been shown to co-localize with other proteins at plasma membranes . For dual staining with ErbB2, separate fluorophores with minimal spectral overlap should be used since these proteins show co-localization patterns in membrane structures of specific cell types .

What are the recommended protocols for co-immunoprecipitation studies involving SH3BGRL3?

Co-immunoprecipitation (co-IP) studies with SH3BGRL3 require careful consideration of protein interactions and buffer conditions. Based on published methodologies, researchers should consider using FLAG-tagged SH3BGRL3 constructs, as available anti-SH3BGRL3 antibodies demonstrate good sensitivity for denatured protein but poor binding to in situ folded protein . When preparing lysates, use buffer conditions that preserve calcium-dependent interactions, as SH3BGRL3's binding to myosin 1c has been shown to be Ca²⁺-dependent . A recommended approach involves transfecting cells (e.g., SKBR3 cells for cancer studies) with FLAG-SH3BGRL3 constructs, then using anti-FLAG-coupled resin for immunoprecipitation followed by Western blot analysis with antibodies against potential binding partners . When investigating interactions with cytoskeletal proteins such as myosin 1c, adseverin, or actin (all identified as potential SH3BGRL3 binding partners), avoid harsh detergents that might disrupt these associations . For validation of interactions, reciprocal co-IP should be performed, pulling down with antibodies against the suspected binding partner and probing for SH3BGRL3 .

What considerations are important when designing RNA interference experiments targeting SH3BGRL3?

RNA interference experiments targeting SH3BGRL3 require careful design to ensure specificity and functional relevance. When designing siRNA or shRNA constructs, target sequences unique to SH3BGRL3 that avoid homology with other SH3BGRL family members to prevent off-target effects. Based on migration studies in MDA-MB-231 cells, knockdown of SH3BGRL3 significantly impairs cell migration capabilities, making this a useful functional readout for successful interference . Include appropriate controls, including scrambled sequences and rescue experiments with exogenous SH3BGRL3 constructs containing silent mutations that render them resistant to the interfering RNA. For phenotypic analysis, prioritize assays related to cell motility, cytoskeletal organization, and calcium-dependent signaling pathways, as these represent known functional domains of SH3BGRL3 activity . When interpreting results, consider that SH3BGRL3 interacts with multiple protein partners, including myosin 1c, adseverin, and actin, so phenotypic effects may result from disruption of various protein complexes rather than a single pathway .

How does SH3BGRL3 interact with myosin 1c and what is the significance of this interaction?

SH3BGRL3 binds specifically to myosin 1c (Myo1c) in a calcium-dependent manner, with the interaction occurring at the IQ-bearing neck region of Myo1c . This interaction was confirmed through multiple methodologies, including co-immunoprecipitation assays and mass spectrometry analysis in SKBR3 cells expressing FLAG-tagged SH3BGRL3 . The calcium dependency of this interaction suggests a regulatory mechanism that may respond to cellular calcium fluctuations. Functionally, this interaction appears to be significant for cell migration, as RNA interference of SH3BGRL3 in MDA-MB-231 cells significantly impaired migration, while overexpression enhanced motility . The binding of SH3BGRL3 to Myo1c may modulate the latter's function in membrane dynamics and cytoskeletal organization. Myo1c is a non-conventional monomeric myosin involved in various cellular processes including membrane trafficking, cytoskeletal dynamics, and mechanotransduction . Therefore, the SH3BGRL3-Myo1c interaction likely represents a regulatory node in pathways controlling cell shape, adhesion, and movement, with particular relevance to cancer cell behaviors such as invasion and metastasis.

How does SH3BGRL3 influence cell migration and cytoskeletal organization?

SH3BGRL3 plays a significant role in regulating cell migration through its interactions with cytoskeletal components. RNA interference studies in MDA-MB-231 cells demonstrated that knockdown of SH3BGRL3 dramatically impaired migration capability, while overexpression enhanced motility . This functional effect is likely mediated through SH3BGRL3's interactions with key cytoskeletal proteins identified through mass spectrometry analysis: myosin 1c, adseverin (an F-actin severing protein), and actin itself . The calcium-dependent binding of SH3BGRL3 to myosin 1c particularly suggests a mechanism for dynamic regulation of cytoskeletal contractility and membrane dynamics in response to calcium signaling . SH3BGRL3 may function as a molecular adaptor that coordinates the activities of these cytoskeletal proteins, facilitating the orchestrated remodeling required for cell movement. Additionally, SH3BGRL3's co-localization with ErbB2 at plasma membranes indicates potential involvement in signaling pathways that trigger cytoskeletal reorganization in response to external stimuli . These multiple interactions position SH3BGRL3 as a nexus in the molecular networks controlling cell motility, with particular relevance to cancer cell invasion and metastasis processes.

What are common technical challenges when using SH3BGRL3 antibodies and how can they be addressed?

Researchers working with SH3BGRL3 antibodies commonly encounter several technical challenges. A significant issue is the differential sensitivity of antibodies to denatured versus in situ folded protein, with several available antibodies showing good sensitivity for denatured SH3BGRL3 but poor binding to the folded protein in cellular contexts . This can be addressed by using epitope-tagged constructs (such as FLAG-SH3BGRL3) for certain applications like immunofluorescence or immunoprecipitation . Another challenge is the relatively small size of SH3BGRL3 (10 kDa), which can make it difficult to resolve from antibody light chains in immunoprecipitation experiments followed by Western blotting . This can be mitigated by using HRP-conjugated protein A/G for detection instead of secondary antibodies, or by cross-linking the primary antibody to the immunoprecipitation beads. Additionally, when studying SH3BGRL3's calcium-dependent interactions, careful attention must be paid to buffer composition, as chelating agents like EDTA can disrupt these interactions . For applications requiring high specificity, researchers should validate antibodies for potential cross-reactivity with other SH3BGRL family members through appropriate controls including siRNA knockdown validation.

How can researchers optimize Western blot protocols for detecting the low molecular weight SH3BGRL3 protein?

Detecting SH3BGRL3 (10 kDa) by Western blot requires specific optimization steps to account for its low molecular weight. Use higher percentage polyacrylamide gels (15-20%) to adequately resolve proteins in the 10-15 kDa range . Transfer protocols should be adapted for small proteins, using lower methanol concentrations (10-15%) in the transfer buffer and shorter transfer times (60-90 minutes) at lower voltages to prevent the protein from passing through the membrane . PVDF membranes with 0.2 μm pore size are preferable to standard 0.45 μm membranes for retaining small proteins . For blocking, 5% BSA often provides better results than milk-based blockers when working with phospho-specific antibodies or when milk proteins cause background issues at low molecular weights. The recommended dilution range for SH3BGRL3 antibodies in Western blot applications is generally between 1:500-1:2000, but this should be empirically determined for each specific antibody and experimental setup . When probing for SH3BGRL3, positive control lysates from PC-3 or U-251 cells are recommended as these have been validated to express detectable levels of the protein . Finally, enhanced chemiluminescence detection systems with longer exposure times may be necessary due to the relatively low abundance of SH3BGRL3 in many cell types.

What controls should be included when validating SH3BGRL3 antibody specificity?

Rigorous validation of SH3BGRL3 antibody specificity requires a comprehensive set of controls. Primary validation should include Western blot analysis comparing cells with known SH3BGRL3 expression (such as PC-3 or U-251 cells) to those where SH3BGRL3 has been knocked down using siRNA or CRISPR-Cas9 methods . The detection of a single band at the expected molecular weight (10 kDa) that diminishes in knockdown samples strongly indicates specificity . Peptide competition assays provide another layer of validation, where pre-incubation of the antibody with the immunizing peptide should abolish specific staining in Western blot or immunohistochemistry applications . For cross-reactivity assessment, especially between species, include samples from multiple organisms when the antibody claims multi-species reactivity (human, mouse, rat) . When available, recombinant SH3BGRL3 protein can serve as a positive control, while recombinant proteins of related family members (SH3BGRL, SH3BGRL2) can help assess potential cross-reactivity within the protein family. For immunohistochemistry applications, include isotype controls and tissues known to be negative for SH3BGRL3 expression alongside positive controls like human stomach cancer tissue .

How can SH3BGRL3 antibodies be employed in studying calcium-dependent protein interactions?

SH3BGRL3's calcium-dependent binding to myosin 1c offers a valuable model system for studying calcium-regulated protein interactions. Researchers can employ SH3BGRL3 antibodies in calcium titration co-immunoprecipitation experiments, where binding assays are performed across a range of free calcium concentrations (typically from <10 nM to >10 μM) to determine the calcium sensitivity threshold of the interaction . For visualizing these interactions in living cells, bimolecular fluorescence complementation (BiFC) assays can be developed using SH3BGRL3 and myosin 1c tagged with complementary fluorescent protein fragments, combined with calcium indicators to correlate interaction dynamics with calcium fluctuations. Proximity ligation assays (PLA) using SH3BGRL3 antibodies together with antibodies against interaction partners like myosin 1c can provide spatial information about where these calcium-dependent interactions occur within the cell . For more detailed biochemical characterization, pull-down assays using recombinant SH3BGRL3 as bait can be performed with varying calcium concentrations, followed by mass spectrometry analysis to identify the complete calcium-dependent interactome. These approaches collectively can reveal how calcium signaling modulates SH3BGRL3's role in cytoskeletal organization and cell migration, potentially uncovering new therapeutic targets for modulating these processes in disease contexts.

What emerging roles of SH3BGRL3 in cancer biology can be investigated using available antibodies?

SH3BGRL3's emerging roles in cancer biology open several promising research directions using available antibodies. Tissue microarray (TMA) analysis with SH3BGRL3 antibodies can establish expression patterns across cancer types and correlate with clinical outcomes to expand on its identified role as a prognostic biomarker in urothelial carcinoma . Multiplexed immunofluorescence combining SH3BGRL3 antibodies with markers for EGFR/ErbB2 signaling pathways can map their spatial relationships in tumor microenvironments . Given SH3BGRL3's role in cell migration, invasion assays comparing SH3BGRL3-high versus SH3BGRL3-low populations (identified by FACS using conjugated antibodies) can determine if expression levels correlate with metastatic potential . Chromatin immunoprecipitation sequencing (ChIP-seq) studies targeting transcription factors regulating SH3BGRL3 expression can identify upstream control mechanisms potentially dysregulated in cancer. For therapeutic development, researchers might screen for small molecules disrupting SH3BGRL3's interaction with myosin 1c, using co-immunoprecipitation with SH3BGRL3 antibodies as a readout . Additionally, exploring SH3BGRL3's potential role in modulating response to EGFR/ErbB2-targeted therapies could reveal whether it functions as a resistance factor or sensitivity marker, informing more personalized treatment approaches.

How can SH3BGRL3 antibodies contribute to understanding the protein's role in glutaredoxin modulation?

SH3BGRL3's proposed function as a modulator of glutaredoxin biological activity represents an under-explored aspect that can be investigated using available antibodies . Researchers can design co-immunoprecipitation experiments using SH3BGRL3 antibodies to pull down protein complexes from cells under various oxidative stress conditions, followed by activity assays to measure glutaredoxin enzymatic function in these complexes. Proximity ligation assays (PLA) combining SH3BGRL3 antibodies with antibodies against glutaredoxin family members can establish if and where these proteins interact within the cell, particularly in response to redox perturbations. For functional studies, cells with SH3BGRL3 knockdown versus overexpression can be subjected to oxidative stress, with subsequent immunofluorescence using SH3BGRL3 antibodies to track its subcellular localization changes. Targeted mass spectrometry approaches using immunoprecipitated SH3BGRL3 can identify post-translational modifications (particularly oxidation-sensitive cysteine modifications) that might regulate its interaction with glutaredoxin. Additionally, in vitro binding studies using recombinant SH3BGRL3 and glutaredoxin proteins under different redox conditions can determine if their interaction is directly redox-regulated. These approaches would significantly advance our understanding of SH3BGRL3's role in cellular redox homeostasis, potentially revealing new connections between cytoskeletal dynamics and redox signaling pathways.